570416-36-3

Basic information

• Product Name: 3(2H)-Pyridazinone,6-(1-methylethyl)-
• Synonyms: 3(2H)-Pyridazinone,6-(1-methylethyl)-;6-ISOPROPYL-3-PYRIDAZINONE;3-propan-2-yl-1H-pyridazin-6-one
• CAS NO: 570416-36-3
• Molecular Formula: C₇H₁₀N₂O
• Molecular Weight: 138.17
• Mol File: 570416-36-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3(2H)-Pyridazinone,6-(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Pyridazinone,6-(1-methylethyl)-(570416-36-3)
• EPA Substance Registry System: 3(2H)-Pyridazinone,6-(1-methylethyl)-(570416-36-3)

Safety Data

• Hazardous Substances Data: 570416-36-3(Hazardous Substances Data)

Usage

General Description

3(2H)-Pyridazinone,6-(1-methylethyl)-, also known as metizoline, is a chemical compound with the molecular formula C10H12N2O. It is a pharmacologically active substance that has been used as a nasal decongestant and vasoconstrictor. Metizoline works by constricting the blood vessels in the nasal passages, which reduces swelling and congestion, making it easier to breathe. It has also been investigated for its potential use in the treatment of migraines. However, its use has been limited due to concerns about its potential cardiovascular side effects. Despite its potential medical applications, metizoline is not widely used in clinical practice and its use is largely limited to research purposes.

Upstream product

• 563-80-4 3-methyl-butan-2-one 
• 298-12-4 Glyoxilic acid 
• 210230-80-1 6-isopropyl-4,5-dihydro-3(2H) pyridazinone 

Downstream Products

• 570416-35-2 3-chloro-6-isopropylpyridazine 
• 1161737-28-5 6-isopropyl-2-(3-{5-[1-(2-morpholin-4-ylethyl)-1H-pyrazol-4-yl]pyrimidin-2-yl}benzyl)-2H-pyridazin-3-one 
• 1086383-70-1 3-bromo-6-isopropylpyridazine 

Relevant articles and documents

Synthesis of a CGRP Receptor Antagonist via an Asymmetric Synthesis of 3-Fluoro-4-aminopiperidine

A practical and efficient enantioselective synthesis of the calcitonin gene-related peptide receptor antagonist 1 has been developed. The key structural component of the active pharmaceutical ingredient is a syn-1,2-amino-fluoropiperidine 4. Two approaches were developed to synthesize this important pharmacophore. Initially, Ru-catalyzed asymmetric hydrogenation of fluoride-substituted enamide 8 enabled the synthesis of sufficient quantities of compound 1 to support early preclinical studies. Subsequently, a novel, cost-effective route to this intermediate was developed utilizing a dynamic kinetic asymmetric transamination of ketone 9. This synthesis also features a robust Ullmann coupling to install a bis-aryl ether using a soluble Cu(I) catalyst. Finally, an enzymatic desymmetrization of meso-diester 7 was exploited for the construction of the γ-lactam moiety in 1.

FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME

The present invention provides a compound represented by the formula: wherein Q represents a fused heterocyclic group, X and Y are the same or different and each represent an optionally halogenated lower alkyl group, an optionally halogenated lower alkoxy group, etc. , or a salt thereof, as well as a herbicide comprising the compound or a salt thereof, which exhibits a significant effect for control of sulfonylurea herbicide-resistant weeds in paddy fields and can reduce the number of active ingredients in a combined preparation and a method of controlling sulfonylurea herbicide-resistant weeds which comprises using the same.